Evidence map›Paper›PMID 20529129›Full record

ArticleThe European journal of neuroscience2010

Secretagogin is a Ca2+-binding protein identifying prospective extended amygdala neurons in the developing mammalian telencephalon.

Jan Mulder, Lauren Spence, Giuseppe Tortoriello, Jennifer A Dinieri, Mathias Uhlén, Bo Shui, Michael I Kotlikoff, Yuchio Yanagawa, Fabienne Aujard, Tomas Hökfelt and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The European journal of neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Neuronal activity modulates the expression of secretagogin, a CaActa physiologica (Oxford, England) · 2025
    Article
  3. Article
  4. Secretagogin marks amygdaloid PKCδ interneurons and modulates NMDA receptor availability.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. 20 Years of Secretagogin: Exocytosis and Beyond.Frontiers in molecular neuroscience · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Jan MulderEuropean Neuroscience Institute at Aberdeen, University of Aberdeen, Aberdeen, UK.
Lauren Spence
Giuseppe Tortoriello
Jennifer A Dinieri
Mathias Uhlén
Bo Shui
Michael I Kotlikoff
Yuchio Yanagawa
Fabienne Aujard
Tomas Hökfelt
Yasmin L Hurd
Tibor Harkany
University of Aberdeen · GBCornell University · USIcahn School of Medicine at Mount Sinai · USAlbaNova · SEJapan Science and Technology Agency · JPKarolinska Institutet · SEMécanismes Adaptatifs et Evolution · FR

Funding

The Opioid mesolimbic system in heroin abuseR01DA015446 · NIDA · KAROLINSKA INSTITUTE · PI HURD, YASMIN L. · 2002 to 2018
$7.1M
The neuronal basis of cannabis-induced developmental deficits in the CNSR01DA023214 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HURD, YASMIN L. · 2008 to 2012
$1.6M
Medical Research CouncilNIDA NIH HHS DA023214NIDA NIH HHS R01 DA015446NIDA NIH HHS R01 DA023214
6 · The paper itself

Abstract

The Ca(2+)-binding proteins (CBPs) calbindin D28k, calretinin and parvalbumin are phenotypic markers of functionally diverse subclasses of neurons in the adult brain. The developmental dynamics of CBP expression are precisely timed: calbindin and calretinin are present in prospective cortical interneurons from mid-gestation, while parvalbumin only becomes expressed during the early postnatal period in rodents. Secretagogin (scgn) is a CBP cloned from pancreatic beta and neuroendocrine cells. We hypothesized that scgn may be expressed by particular neuronal contingents during prenatal development of the mammalian telencephalon. We find that scgn is expressed in neurons transiting in the subpallial differentiation zone by embryonic day (E)11 in mouse. From E12, scgn(+) cells commute towards the extended amygdala and colonize the bed nucleus of stria terminalis, the interstitial nucleus of the posterior limb of the anterior commissure, the dorsal substantia innominata (SI) and the central and medial amygdaloid nuclei. Scgn(+) neurons can acquire a cholinergic phenotype in the SI or differentiate into GABA cells in the central amygdala. We also uncover phylogenetic differences in scgn expression as this CBP defines not only neurons destined to the extended amygdala but also cholinergic projection cells and cortical pyramidal cells in the fetal nonhuman primate and human brains, respectively. Overall, our findings emphasize the developmentally shared origins of neurons populating the extended amygdala, and suggest that secretagogin can be relevant to the generation of functional modalities in specific neuronal circuitries.

Indexed as

TelencephalonAmygdalaAnimalsCalcium-Binding ProteinsCheirogaleidaeEmbryo, MammalianFemaleGene Expression ProfilingHumansMammalsMiceNeuronsOrganogenesisSecretagoginsCalcium-Binding ProteinsSCGN protein, humanSecretagogins

Identifiers

PMID20529129
PMCPMC2917754
OpenAlexW1525253519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.